Results 301 to 310 of about 113,542 (365)
Some of the next articles are maybe not open access.
Tamoxifen-induced QT interval prolongation
Journal of Clinical Pharmacy and Therapeutics, 2008We report on a case of tamoxifen-induced QT interval prolongation in a 56-year-old-female patient with hormone-dependent carcinoma of the right breast, stage T2N0M0, grade 3 and HER-2 negative. Partial mastectomy with axillary lymph node excision was performed in July 2007 with adjuvant hormonal and radiation therapy.
L, Slovacek +4 more
openaire +2 more sources
Gatifloxacin and Prolonged QT Interval
The American Journal of the Medical Sciences, 2004We report the case of a 54-year-old woman who, while being treated for acute sinusitis with gatifloxacin, presented with syncope and was found to have a markedly prolonged QT interval. After stopping gatifloxacin, the QT interval normalized. We speculate that her episode of syncope was caused by a ventricular arrhythmia that resulted from an increased ...
Shoaib R, Ansari, Nagesh, Chopra
openaire +2 more sources
Aliskiren-Induced QT Interval Prolongation
Southern Medical Journal, 2009Aliskiren gained FDA approval for the treatment of hypertension in 2007. It is the first approved pharmaceutical to manage hypertension by direct renin inhibition. With the introduction of novel drugs and mechanisms of action comes the challenge of monitoring for new unreported adverse events.
Gregory J, Peitz +2 more
openaire +2 more sources
Biventricular Pacing and QT Interval Prolongation
Journal of Cardiovascular Electrophysiology, 2007Introduction: The purpose of this study was to examine BiV pacing‐dependent changes in QT interval and the related potential for proarrhythmia. Biventricular (BiV) pacing has emerged as a promising therapy for patients with advanced congestive heart failure (CHF) and bundle branch block (BBB).
Atul, Bhatia +5 more
openaire +2 more sources
Protease Inhibitor–Associated QT Interval Prolongation
Annals of Pharmacotherapy, 2011Objective: To evaluate the literature on protease inhibitor (PI)-associated QT interval prolongation and risk for torsade de pointes in patients infected by HIV. Data Sources: Primary literature was identified through MEDLINE (1950-August 2011) and EMBASE (1980-August 2011), using the following search terms: antiretroviral agents, HIV, protease ...
Kimberley, Hunt +2 more
openaire +2 more sources
Prolonged QT interval and cocaine use
Journal of Electrocardiology, 1997Cardiovascular consequences of cocaine use are well known, and surveillance for them is common practice in the routine care of cocaine abusers. However, the cardiac electrical abnormalities that arise, although studied in animal experiments, lack correlation with human reports.
R, Perera, A, Kraebber, M J, Schwartz
openaire +2 more sources
Antipsychotic Drugs and QT Interval Prolongation
Psychiatric Quarterly, 2003The QTc prolongation by antipsychotic drugs is of major concern, especially in light of the data indicating an increased risk of sudden death in psychiatric patients taking these drugs. Sudden death in psychiatric patients could be partially attributed to drug-induced torsades de pointes and for this reason careful evaluation of QTc prolonging ...
Wojciech, Zareba, David A, Lin
openaire +2 more sources
QT-Interval Prolongation Produced by Probucol
Archives of Internal Medicine, 1981To the Editor. —Probucol (4,4′-[(1-methylethylidene) bis (thio)] bis [2,6-bis(1,1-dimethylethyl) phenol]) is a recently introduced drug for the lowering of serum cholesterol levels in familial hypercholesterolemia type II. 1,2 Side effects are considered slight, and no ECG abnormalities have been reported in humans receiving probucol. 2,3 This article
openaire +2 more sources
Drug-Induced Prolongation of the QT Interval
New England Journal of Medicine, 2004The single most common cause of the withdrawal or restriction of the use of marketed drugs has been QT-interval prolongation associated with polymorphic ventricular tachycardia, or torsade de pointes, a condition that can be fatal. This review summarizes the current knowledge about molecular and clinical predictors of drug-induced QT-interval ...
Curigliano G, Cipolla C, de Braud F
openaire +3 more sources
Screening lead compounds for QT interval prolongation
Drug Discovery Today, 2001The late detection of cardiotoxic side effects, such as QT prolongation, induced by compounds of pharmacological interest can dramatically impede drug discovery and development projects, and consequently increase their cost. The launch of new drugs with undetected cardiotoxic side effects could have hazardous consequences and could trigger lethal ...
R, Netzer +3 more
openaire +2 more sources